Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019599 | 0.89 | HPGD (1.00) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL16268464 | 0.88 | TSHR (0.80) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24209661 | 0.85 | MAPT (0.64) | HPGDMEN1KMT2AMAPK1TSHR | |
| SCHEMBL24019576 | 0.85 | HPGD (0.74) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24209697 | 0.81 | ALDH1A1 (0.82) | MEN1KMT2AATMALDH1A1PPARG | |
| SCHEMBL24019594 | 0.79 | TP53 (0.72) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL21951986 | 0.78 | MAPT (0.71) | HPGDMEN1KMT2AMAPK1TSHR | |
| SCHEMBL24209699 | 0.78 | HPGD (0.79) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24019591 | 0.77 | SMN1; SMN2 (0.69) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL22010011 | 0.77 | HPGD (0.67) | HPGDMEN1KMT2AMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | HPGD 2761/4885MEN1 3372/4885KMT2A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.